Exelixis (EXEL) PT Bumped to $8 at Piper Jaffray, Remains Sidelined
Get Alerts EXEL Hot Sheet
Rating Summary:
18 Buy, 5 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 7
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff raised his price target on Exelixis (NASDAQ: EXEL) to $8.00 (from $5.00) but maintained a Neutral rating following results.
Tenthoff commented, "Exelixis reported COMETRIQ sales of $14M in 2Q:16 and CABOMETYX renal cell carcinoma (RCC) sales of $17.6M including $6.5-7M in inventory stocking. These results beat our sales estimate of $10.5 million in COMETRIQ and $7.5 million of CABOMETYX. We now forecast U.S. CABOMETYX sales of $88M in 2016 and $224M in 2017. Exelixis ended 1Q:16 with cash of $384M, retains a $287.5M convertible note due in 2019 and owes Silicon Valley Bank $80M and Deerfield $107M due in July 2018. We remain Neutral, however are increasing our price target to $8 from $5 based on increased CABOMETYX sales."
For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.
Shares of Exelixis closed at $9.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
- BofA Securities Upgrades Tesla (TSLA) to Buy on wind up of positive catalysts
- Tesla (TSLA) PT Lowered to $180 at Mizuho
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!